{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:20Z","timestamp":1791581900612,"version":"4.3.4"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The MYC pathway is highly activated in gastric cancer (GC), but the MYC oncogene\u2019s structural biology makes direct pharmacological inhibition very difficult. We hypothesized that BRD4, as a major co-activator of MYC, maintains MYC-dependent survival circuits, thus making BRD4 a key therapeutic vulnerability in late GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We carried out a comprehensive transcriptomic analysis by utilizing large-scale data sets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), then these computational forecasts were later verified in strict clinical cohorts via molecular and histological methods. Functional verification was done through genetic and pharmacological interference by means of CRISPR-Cas9 gene deletion and PROTAC-induced protein breakdown with ARV771, ultimately, the therapeutic efficacy and systemic safety of these interventions were assessed\n                      <jats:italic>in vivo<\/jats:italic>\n                      with mouse xenograft models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analyses revealed that the expression of BRD4 was significantly increased in GC tissues and there was a strong connection between this increase and the MYC hyperactivation, advanced TNM staging, and shortened patient survival. Our knockout (KO) experiments found that the viability of tumor cells depended greatly on the BRD4 - MYC - BCL2 signaling pathway because when BRD4 was depleted, the expression of BCL2, a crucial anti-apoptotic protein, decreased substantially. When pharmacological intervention was applied using ARV771, these cancer-related characteristics were effectively reversed, resulting in the suppression of tumor proliferation, the decrease of BCL2 levels, and significant inhibition of the growth of xenograft tumors\n                      <jats:italic>in vivo<\/jats:italic>\n                      without observable toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that BRD4 acts a chief epigenetic controller which promotes the progress of GC by intensifying MYC-dependent survival and ARV771 blocks this survival advantage, thus presenting a highly compelling rationale for integrating BRD4 degraders into modern targeted regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1835830","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:52:51Z","timestamp":1782276771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting BRD4 in gastric cancer: promoting apoptosis and suppressing tumor progression"],"prefix":"10.3389","volume":"17","author":[{"given":"Xu-Liang","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hai","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiuLi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Laboratory of Precision Therapeutics, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1634\/theoncologist.2014-0378","article-title":"Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies","volume":"20","author":"Ali","year":"2015","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/jcb.26264","article-title":"BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c\u2010MYC","volume":"119","author":"Ba","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e12314","DOI":"10.7717\/peerj.12314","article-title":"The role of zinc transporter proteins as predictive and prognostic biomarkers of hepatocellular cancer","volume":"9","author":"Bitirim","year":"2021","journal-title":"PeerJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.3892\/ol.2018.7909","article-title":"Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer","volume":"15","author":"Byun","year":"2018","journal-title":"Oncol. Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12967-019-1941-0","article-title":"Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing","volume":"17","author":"Cai","year":"2019","journal-title":"J. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41419-021-03904-4","article-title":"USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor alpha","volume":"12","author":"Cao","year":"2021","journal-title":"Cell. Death Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.it.2017.01.002","article-title":"MYC: master regulator of immune privilege","volume":"38","author":"Casey","year":"2017","journal-title":"Trends Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.21147\/j.issn.1000-9604.2021.02.04","article-title":"Surgical treatment of gastric cancer: current status and future directions","volume":"33","author":"Chen","year":"2021","journal-title":"Chin. J. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"858901","DOI":"10.3389\/fphar.2022.858901","article-title":"ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","article-title":"Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. and Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15321","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"Hsu","year":"2015","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10120-024-01499-1","article-title":"Family history and gastric cancer incidence and mortality in Asia: a pooled analysis of more than half a million participants","volume":"27","author":"Huang","year":"2024","journal-title":"Gastric Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/jco.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.2147\/OTT.S315252","article-title":"Recent advances in systemic treatments for HER-2 positive advanced gastric cancer","volume":"14","author":"Kahraman","year":"2021","journal-title":"OncoTargets Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.21147\/j.issn.1000-9604.2021.02.01","article-title":"Laparoscopic surgery for gastric cancer: current status and future direction","volume":"33","author":"Kang","year":"2021","journal-title":"Chin. J. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat. Struct. and Mol. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4143\/crt.2005.37.2.79","article-title":"Chemotherapy for advanced gastric cancer: slow but further progress","volume":"37","author":"Kim","year":"2005","journal-title":"Cancer Res. Treat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fphar.2018.00404","article-title":"Emerging therapies in the management of advanced-stage gastric cancer","volume":"9","author":"Kumar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-018-4653-6","article-title":"Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1158\/1078-0432.ccr-12-3629","article-title":"Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. and Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3892\/ijo.2019.4885","article-title":"Differences in the prognosis of gastric cancer patients of different sexes and races and the molecular mechanisms involved","volume":"55","author":"Li","year":"2019","journal-title":"Int. J. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41420-023-01403-3","article-title":"The effects of MYC on tumor immunity and immunotherapy","volume":"9","author":"Li","year":"2023","journal-title":"Cell. Death Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.mtbio.2025.101696","article-title":"A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer","volume":"32","author":"Li","year":"","journal-title":"Mater. Today bio."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117418","DOI":"10.1016\/j.bcp.2025.117418","article-title":"Bromodomain containing protein 4 (BRD4) and cancer therapy: a glimpse at dual-target drug development","volume":"242","author":"Li","year":"","journal-title":"Biochem. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.gastro.2021.03.023","article-title":"Global patterns and trends in gastric cancer incidence rates (1988-2012) and predictions to 2030","volume":"161","author":"Lin","year":"2021","journal-title":"Gastroenterology"},{"key":"B34","first-page":"5728","article-title":"BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells","volume":"11","author":"Lu","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12672-025-01759-1","article-title":"Single-cell RNA-sequencing and genome-wide Mendelian randomisation along with abundant machine learning methods identify a novel B cells signature in gastric cancer","volume":"16","author":"Ma","year":"2025","journal-title":"Discov. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"a014407","DOI":"10.1101\/cshperspect.a014407","article-title":"MYC and the control of apoptosis","volume":"4","author":"Mcmahon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s10120-016-0603-7","article-title":"A rising trend in the incidence of advanced gastric cancer in young Hispanic men","volume":"20","author":"Merchant","year":"2017","journal-title":"Gastric Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3238\/arztebl.2011.0698","article-title":"Treatment strategies in gastric cancer","volume":"108","author":"Meyer","year":"2011","journal-title":"Dtsch. Arztebl. Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.3390\/cancers13143470","article-title":"The BET inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancer","volume":"13","author":"Miller","year":"2021","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaoncol.2017.2805","article-title":"Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer","volume":"4","author":"Mokdad","year":"2018","journal-title":"JAMA Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1074\/mcp.RA118.001181","article-title":"Carcinogenic Helicobacter pylori strains selectively dysregulate the in vivo gastric proteome, which may be associated with stomach cancer progression","volume":"18","author":"Noto","year":"2019","journal-title":"Mol. Cell. Proteomics."},{"key":"B45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"27","author":"Ogata","year":"1999","journal-title":"Nucleic. acids. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-020-00774-4","article-title":"Targeted therapies in advanced gastric cancer","volume":"21","author":"Patel","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.v120.21.542.542","article-title":"MYC translocation partner gene determines survival in large B-Cell lymphoma with MYC- or double hit MYC\/BCL2 translocation","volume":"120","author":"Pedersen","year":"2012","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"200935","DOI":"10.1016\/j.omton.2025.200935","article-title":"BTK inhibitors are a possible emerging therapeutic target for gastric cancer","volume":"33","author":"Portillo-Mino","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s12276-023-01062-5","article-title":"SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK\/ERK and PI3K\/AKT pathways","volume":"55","author":"Ren","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature13537","article-title":"Selective transcriptional regulation by myc in cellular growth control and lymphomagenesis","volume":"511","author":"Sab\u00f2","year":"2014","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10120-016-0601-9","article-title":"Proposal of a new stage grouping of gastric cancer for TNM classification: International gastric cancer association staging project","volume":"20","author":"Sano","year":"2016","journal-title":"Gastric Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-019-0149-6","article-title":"Targeted and novel therapy in advanced gastric cancer","volume":"8","author":"Selim","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/cancers15092639","article-title":"Updated epidemiology of gastric cancer in Asia: decreased incidence but still a big challenge","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers"},{"key":"B54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/ijms18030235","article-title":"Overexpression of transforming acidic coiled coil-containing protein 3 reflects malignant characteristics and poor prognosis of glioma","volume":"18","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3892\/ijo.2018.4577","article-title":"Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression","volume":"53","author":"Tan","year":"2018","journal-title":"Int. J. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","article-title":"SRplot: a free online platform for data visualization and graphing","volume":"18","author":"Tang","year":"2023","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1073\/pnas.1910391116","article-title":"Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance","volume":"116","author":"Thomas","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"CD004064","DOI":"10.1002\/14651858.CD004064.pub4","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature13473","article-title":"Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles","volume":"511","author":"Walz","year":"2014","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40659-017-0124-9","article-title":"BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma","volume":"50","author":"Wang","year":"2017","journal-title":"Biol. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ije\/dyy055","article-title":"Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis","volume":"47","author":"Wang","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12672-024-01168-w","article-title":"Characterize molecular signatures and establish a prognostic signature of gastric cancer by integrating single-cell RNA sequencing and bulk RNA sequencing","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1093\/nar\/gku463","article-title":"ChIP-Enrich: gene set enrichment testing for ChIP-seq data","volume":"42","author":"Welch","year":"2014","journal-title":"Nucleic. acids. Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","article-title":"MYC in cancer: from undruggable target to clinical trials","volume":"24","author":"Whitfield","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/sla.0000000000001523","article-title":"A novel prediction model of prognosis after gastrectomy for gastric carcinoma","volume":"264","author":"Woo","year":"2016","journal-title":"Ann. Surg."},{"key":"B69","doi-asserted-by":"publisher","first-page":"105848","DOI":"10.1016\/j.bioorg.2022.105848","article-title":"Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery","volume":"125","author":"Xi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cellsig.2017.10.010","article-title":"Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma","volume":"42","author":"Xiang","year":"2018","journal-title":"Cell. Signal."},{"key":"B71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13046-018-0795-2","article-title":"PTEN lipid phosphatase inactivation links the hippo and PI3K\/Akt pathways to induce gastric tumorigenesis","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1555649","DOI":"10.3389\/fonc.2025.1555649","article-title":"PSMD11 and PSMD14 may serve as novel biomarkers for the prognosis of pancreatic ductal adenocarcinoma","volume":"15","author":"Yang","year":"2025","journal-title":"Front. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12964-015-0111-0","article-title":"Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways","volume":"13","author":"Yong","year":"2015","journal-title":"Cell. Commun. Signal."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2165\/11592530-000000000-00000","article-title":"Targeted therapies for gastric cancer: current status","volume":"71","author":"Yoong","year":"2011","journal-title":"Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS A J. Integr. Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/or.2015.4528","article-title":"Targeted therapy for gastric cancer: current status and future directions","volume":"35","author":"Yuan","year":"2016","journal-title":"Oncol. Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0394632015572070","article-title":"BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"28","author":"Zhang","year":"2015","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1468488","DOI":"10.3389\/fonc.2024.1468488","article-title":"Global, regional, and national trends in gastric cancer burden: 1990-2021 and projections to 2040","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.apsb.2025.01.007","article-title":"Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1835830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:53:01Z","timestamp":1782276781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1835830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":80,"alternative-id":["10.3389\/fphar.2026.1835830"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1835830","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1835830"}}